Sangamo Announces AAV Capsid Data
Click here to view
Careers
Core Values
Diversity, Equity and Inclusion
Open Positions
Employee Benefits
Clinical Trials
Contact
Science
Technology Platforms
Zinc Finger Platform
Delivery Platform
CAR-Treg Platform
Therapeutic Applications
Neurology
Autoimmunity and Transplantation
Oncology
Presentations
Publications
Programs
Pipeline
Clinical Programs
Hemophilia A
Fabry Disease
Renal transplantation
Sickle Cell Disease
Clinical Trials
Collaborations & Partners
Patients
Our Commitment
Expanded Access Policy
Bioethics
Patient Stories
Bryan – Fabry Disease
Lori – Fabry Disease
Matt – Fabry Disease
Elizabeth – Fabry Disease
Israel – Hemophilia A
Miles – Hemophilia A
Trevor – Prion Disease
Sharron – Renal Transplant
Patient Focus
Resources
Education
Organizations
Investors & Media
Overview
News Releases
Events
Presentations
ESG
About
Overview
Mission & Vision
Executive Leadership
Board of Directors
Latest News
News Releases
Events
Presentations
Contact
Science
Technology Platforms
Zinc Finger Platform
Delivery Platform
CAR-Treg Platform
Therapeutic Applications
Neurology
Autoimmunity and Transplantation
Oncology
Presentations
Publications
Programs
Pipeline
Clinical Programs
Hemophilia A
Fabry Disease
Renal transplantation
Sickle Cell Disease
Clinical Trials
Collaborations & Partners
Patients
Our Commitment
Expanded Access Policy
Bioethics
Patient Stories
Bryan – Fabry Disease
Lori – Fabry Disease
Matt – Fabry Disease
Elizabeth – Fabry Disease
Israel – Hemophilia A
Miles – Hemophilia A
Trevor – Prion Disease
Sharron – Renal Transplant
Patient Focus
Resources
Education
Organizations
Investors & Media
Overview
News Releases
Events
Presentations
ESG
About
Overview
Mission & Vision
Executive Leadership
Board of Directors
Latest News
News Releases
Events
Presentations
Contact
LinkedIn
Twitter
Scientific & Medical Presentations
Neurology Conference Presentations Hub
WORLDSymposium 2024
Presentation: Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
WORLDSymposium 2024
Poster: Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
WORLDSymposium 2024
Presentation: A 3-month gene therapy single-dose IV administration pharmacology and safety study with ST-920 (isaralgagene civaparvovec) for Fabry disease in mice
WORLDSymposium 2024
Poster: A 3-month gene therapy single-dose IV administration pharmacology and safety study with ST-920 (isaralgagene civaparvovec) for Fabry disease in mice
WORLDSymposium 2024
Poster: Anti-AAV6 antibody assay for patient enrollment supporting ST-920 phase 1/2 study for Fabry disease
ASH 2023
Four-Year Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A
CRL Biotechnology Symposium 2023
Preclinical Development of a Zinc Finger Transcriptional Repressor Targeting the SCN9A Gene as a Novel Therapy for Peripheral Neuropathic Pain
American College of Toxicology 2023
Preclinical Development of a Novel Gene Therapy for the Treatment of Peripheral Neuropathic Pain Through Zinc Finger Repressor- Mediated Repression of the SCN9A Gene
Annual Pain Therapeutics Summit 2023
Zinc finger mediated epigenetic repression of SCN9A gene as a therapeutic approach for painful peripheral neuropathies
ESGCT 2023
Multiplex targeting of immune checkpoints with compact zinc finger repressors to improve anti-tumor activity of T cells
ESGCT 2023
Zinc Finger Activators restore normal gene and protein expression in a mouse model of SCN2A haploinsufficiency
ESGCT 2023
Shank3 Gene Activation Mediated by Zinc Finger Activators (ZF-As) as a Therapeutic Approach for Phelan-McDermid Syndrome
ESGCT 2023
Multimerization of Chimeric Antigen Receptor (CAR) binding domains: A solution to assess tissue specificity of low to medium affinity scFv
Prion 2023
Neuron-Specific Expression of Zinc-Finger Repressors Mediate Widespread Prion Reduction in the Brain for the Potential Treatment of Prion Disease
ASGCT 2023
Zinc Finger Transcriptional Regulator Mediated Repression of SCN9A Gene as a Therapeutic Approach for Painful Peripheral Neuropathies
ASGCT 2023
Engineered Zinc Finger Transcriptional Regulators Specifically Reduce Prion Expression and Extend Survival in an Aggressive Prion Disease Model
ASGCT 2023
Engineered Zinc Finger Transcriptional Regulators Enable Robust and Reliable Epigenetic Regulation in the Mouse Brain
ASGCT 2023
A Robust and Flexible Baculovirus-Insect Cell System for AAV Vector Production with Improved Yield, Capsid Ratios and Potency
ASGCT 2023
Overcoming the Effect of Previous Enzyme Replacement Therapy on the Detection of Anti-Transgene Protein Antibodies After Treatment with Gene Therapy
ASGCT 2023
Gene Activation Mediated by Zinc Finger Transcriptional Regulators (ZF-TRs) as a Therapeutic Approach for CNS Disorders
ASGCT 2023
Evolution of Blood-Brain Barrier Penetrant AAV Capsids in Non-Human Primates Using a Multiplexed Transcription Dependent Capsid Engineering Platform
ASGCT 2023
Strategic Formulation Development for AAV Delivered Gene Therapies – a Case Study
ASGCT 2023
Development of a Competitive Ligand-Binding Assay to Detect Neutralizing Antibodies Against Chimeric Antigen Receptor of Regulatory T Cells
ASGCT 2023
Cell-Type Specific Reduction of Prion Expression in Neurons and Astrocytes Using Engineered Zinc Finger Transcriptional Regulators
ASGCT 2023
Intercellular Zinc Finger Protein Delivery for Cross-Corrective Epigenetic Regulation in the CNS
ASGCT 2023
Fitness Maturation of Engineered AAV Capsids STAC-102 and STAC-103 Enhances Central Nervous System Transduction after CSF Administration in Cynomolgus Macaques
ASGCT 2023
Process and Platform Development for Production and Purification of CNS-Tropic Engineered AAV Capsids
ASGCT 2023
Zinc Finger-Transcriptional Repressors Against Immune Checkpoint Molecules to Improve Anti-Tumor Activity of Gene-Modified T Cells
WORLDSymposium 2023
Poster: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease
WORLDSymposium 2023
Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease
ASH 2022
Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A
ASH 2022
Interim Safety and Efficacy Results From a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1)
Prion 2022
ZF-transcription factors for Prion Disease
NORD 2022
Preliminary results of STAAR, a Phase I/2 study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease and long-term follow-up
ESGCT 2022
Preliminary results of STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease and long term follow up
ESGCT 2022
Engineering of Allogeneic Regulatory T Cells Expressing a Chimeric Antigen Receptor (Allo-CAR-Tregs) Using Zinc Finger Nuclease/AAV6-Mediated Editing
ESGCT 2022
Engineering of Factor IX-secreting B cells using ZF-Nuclease / AAV6 editing technology in a GMP-compatible medium
SSIEM 2022
Preliminary results of STAAR, a Phase I/II study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease and long-term follow-up
ASGCT 2022
Engineered AAV Capsids Exhibit Improved Transduction of the Central Nervous System After CSF Administration in Adult Cynomolgus Macaques
ASGCT 2022
A Compact Zinc Finger Architecture for Highly Efficient Base Editing in Human Cells
ASGCT 2022
STEADFAST: A First-in-Human Study Assessing HLA-A*02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation
ASGCT 2022
Evaluation of a Human Neurovascular Model to Complement a Parallel Non-human Primate Selection for Blood–Brain Barrier Penetrant AAV Capsids
ASGCT 2022
Zinc Finger Nuclease/AAV6-Mediated Factor IX(FIX) Insertion Into B Cells Results in Sustained Therapeutic FIX Levels In Vivo After Using a GMP-Like Differentiation Culture System
ASGCT 2022
Genome Orthogonal Zinc Finger Proteins for the Development of Genomic Medicines
ASGCT 2022
Engineering of Allogeneic Regulatory T Cells Expressing a Chimeric Antigen Receptor(Allo-CAR-Tregs) Using Zinc Finger Nuclease/AAV6-Mediated Editing
ASGCT 2022
Durable, Multiplexed Cell Engineering Using Zinc Finger–Guided Transcriptional Regulators Delivered via a Single Viral Particle
WORLDSymposium 2022
Preliminary Results of the STAAR Study, a Phase I/II Study of Isaralgagene Civaparvovec (ST-920) Gene Therapy in Adults With Fabry Disease
ASH 2021
Preliminary Safety and Efficacy Results from PRECIZN-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD)
ASH 2021
Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF 07055480/SB 525) Gene Therapy in Adults With Severe Hemophilia A
ASH 2021
3974 Updated Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia